←Cardiology & EP
HFpEF — preserved EF
📚
📚 Library › ❤️ Cardiology & EP › Heart failure
🧱

HFpEF — preserved EF

EF ≥50%. Make the diagnosis (H₂FPEF), rule out mimics like amyloid, then SGLT2i + finerenone.

HFpEFH2FPEFfinerenoneamyloidGLP-1
🗓️ Reviewed 2026-11-18 · ⏱️ 3 min read · 📖 2026 ACC ECDP for HFpEF · 2022 AHA/ACC/HFSA HF guideline
🧠 Pathophysiology in 60 seconds🔎 Diagnosis💊 Management (2026 ACC pathway)⚠️ Pitfalls🎓 Board corner📚 References
⚡ Bottom line — first hour
  • HFpEF = HF symptoms + EF ≥50% + proof of high filling pressure (BNP, E/e′, LA size, or invasive).
  • Use H₂FPEF (or HFA-PEFF) when unsure. Obesity lowers BNP.
  • Rule out mimics: ATTR amyloid, HCM, valve disease, constriction, high-output states.
  • 2026 ACC pathway — backbone = SGLT2i + finerenone (finerenone is the MRA of choice; spironolactone if not feasible).
  • BMI ≥30 → add a GLP-1 RA or tirzepatide (STEP-HFpEF, SUMMIT).
  • Diuretics for congestion. β-blockers only for a reason (AF rate, angina, post-MI).

🧠 Pathophysiology in 60 seconds

⌄
  • Stiff LV + stiff vessels + systemic inflammation from visceral fat → high LV filling pressure at rest or with exercise.
  • The 2026 view: HFpEF is a multisystem cardio-kidney-metabolic syndrome, not "just diastolic dysfunction."
  • Exercise → pressure spikes → lung congestion → dyspnea. AF, HTN, CKD, obesity and anemia all add load.
🧩 Think of it like this

HFrEF is a weak pump. HFpEF is a strong pump stuck in a too-small, stiff balloon — every extra drop of volume raises pressure a lot.

🔎 Diagnosis

⌄
H₂FPEF item Points
Heavy: BMI >30 2
Hypertensive: ≥2 BP drugs 1
Fibrillation (AF) 3
Pulmonary HTN: PASP >35 mmHg 1
Elder: age >60 1
Filling: E/e′ >9 1

0–1 low probability · 2–5 intermediate (consider BNP, exercise echo / invasive test) · 6–9 high probability.

⚠️ Mimics to hunt
  • ATTR cardiac amyloid: age >65, bilateral carpal tunnel, spinal stenosis, biceps rupture, low-voltage ECG with thick walls, troponin always a little high → PYP/DPD scan + serum free light chains & SPEP/UPEP/immunofixation (rule out AL first). Treatment: tafamidis / acoramidis.
  • HCM · moderate–severe AS/MR · constrictive pericarditis · high-output (anemia, AV fistula, thyroid, liver) · pulmonary arterial hypertension.

💊 Management (2026 ACC pathway)

⌄
Therapy Who Dose / note
SGLT2i (empagliflozin, dapagliflozin) All confirmed HFpEF 10 mg daily
Finerenone Most patients (K ≤5.0, eGFR ≥25) Start 10–20 mg daily by eGFR; titrate; check K in 4 weeks
Spironolactone If finerenone not possible (cost, access) 12.5–25 mg daily
GLP-1 RA / tirzepatide BMI ≥30 Semaglutide 2.4 mg weekly or tirzepatide — weight, symptoms, HF events
ARNI / ARB Consider, esp. EF in lower range (≤55–60), women Sacubitril/valsartan 24/26 → 97/103 BID
Loop diuretic Congestion Lowest dose that keeps euvolemia
β-blocker Only with AF, angina, post-MI Not routine (blunts heart-rate reserve)
  • Treat BP (<130/80), AF (consider rhythm control), sleep apnea, CKD, diabetes.
  • Exercise training and weight loss improve symptoms.

⚠️ Pitfalls

⌄
  • Labeling every dyspneic obese patient "HFpEF" without objective data.
  • Missing amyloid (and starting high-dose β-blockers/digoxin, poorly tolerated).
  • Over-diuresis → AKI, hypotension (small, stiff LV is preload-dependent).
  • Rate too slow — HFpEF patients need heart-rate reserve.

🎓 Board corner

⌄
Stem Answer
78-year-old man, bilateral carpal tunnel, LVH, low voltage ATTR amyloid → PYP scan + light chains
HFpEF, best proven first drug SGLT2 inhibitor
HFpEF + BMI 38 Add GLP-1 RA / tirzepatide
HFpEF, MRA of choice (2026) Finerenone
EF 55%, dyspnea, BMI 32, BNP normal Obesity lowers BNP → H₂FPEF / exercise testing

📚 References

⌄
  • Kittleson MM, et al. 2026 ACC Expert Consensus Decision Pathway on HFpEF. J Am Coll Cardiol. 2026.
  • Heidenreich PA, et al. 2022 AHA/ACC/HFSA HF guideline.
  • EMPEROR-Preserved · DELIVER · FINEARTS-HF · STEP-HFpEF · SUMMIT · PARAGON-HF.
  • Reddy YNV, et al. H₂FPEF score. Circulation. 2018;138:861.
↩︎ Back to ❤️ Cardiology & EP